Market Research Logo

Global Hepatocellular Carcinoma Drugs Market 2017-2021

About Hepatocellular Carcinoma Drugs

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Technavio’s analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer
  • Eli Lilly
  • Johnson and Johnson
  • Pfizer
Other prominent vendors
  • Bristol-Myers Squibb
  • Celgene
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Salix Pharmaceuticals
  • Transgene
Market driver
  • Growing cases of hepatitis B and C infections
  • For a full, detailed list, view our report
Market challenge
  • Stringent government regulations and trial failure in the late stage of drug development
  • For a full, detailed list, view our report
Market trend
  • Increase in R&D activities for liver cirrhosis medication
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Hepatocellular Carcinoma Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global hepatocellular carcinoma drugs market: Bayer, Eli Lilly, Johnson and Johnson, and Pfizer.

Other Prominent Vendors in the market are: Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increase in R&D activities for liver cirrhosis medication. The need for efficacious and better-tolerated medications drives R&D in the global liver cirrhosis medication market. The growing incidence of the disease represents significant opportunities for market growth. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.”

According to the report, one driver in the market is growing cases of hepatitis B and C infections. HCC development has been related with many etiological conditions such as alcohol, hepatitis virus, and cirrhosis. Chronic infection with HBV and HCV often leads to cirrhosis which further enhances the probability of developing HCC. HBV is a DNA virus that integrates into host genome this is believed to be carcinogenic. On the other hand, HCV is an RNA virus, it does not integrate with the host genome however, it still induces HCC through inflammatory response to the virus or through host protein interaction.

Further, the report states that one challenge in the market is stringent government regulations and trial failure in the late stage of drug development. Drug approval processes are stringent worldwide, demanding evidence from clinical trial studies. Regulatory authorities carefully study and evaluate the safety, efficacy, pharmacological data, pharmacodynamic effects, and interactions of drugs before approving them for use. A drug failing any of these criteria is likely to receive a complete response letter (CRL) or face complete rejection from regulatory agencies. On receiving a CRL, a drug applicant is required to furnish any additional data pertaining to the drug, which includes additional clinical trials, thereby increasing the R&D expenditure on the drug.

Companies Mentioned

Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Table Functions of liver
    • Table Causes of HCC
  • Market landscape
    • Table Global HCC drugs market
    • Market size and forecast
      • Table Global HCC drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global HCC drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline based on vendors
    • Table Key clinical trials
  • Market segmentation by therapy
    • Table Global HCC drugs market segmentation based on therapies
    • Table Global HCC drugs market share as per therapies 2016 and 2021
    • Chemotherapy
      • Table Major types of chemotherapy
      • Table Global HCC chemotherapy drugs market 2016-2021 ($ millions)
      • Table NEXAVAR: Drug overview
      • Table STIVARGA: Drug overview
    • Brachytherapy
      • Table Global HCC brachytherapy drugs market 2016-2021 ($ millions)
    • Ablation therapy
      • Table Global HCC ablation therapy market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global HCC drugs market share by geography 2016 and 2021
    • Table Global HCC drugs market revenues by geography 2016-2021 ($ millions)
    • HCC drugs market in Americas
      • Table Market scenario in Americas
      • Table HCC drugs market in Americas 2016-2021 ($ millions)
      • Table Liver cancer scenario in the US 2016
    • HCC drugs market in EMEA
      • Table Market scenario in EMEA
      • Table HCC drugs market in EMEA 2016-2021 ($ millions)
      • Table Top five countries with highest incidence of liver cancer
    • HCC drugs market in APAC
      • Table Market scenario in APAC
      • Table HCC drugs market in APAC 2016-2021 ($ millions)
      • Table Proportions of HBV and HCV-related HCC in APAC
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Hepatitis C scenario 2016
      • Table Hepatitis B scenario 2016
      • Table Lifestyle disease effect on liver
    • Market challenges
      • Table Global liver transplants scenario 2014
      • Table Percentage distribution of transplants by organ in the US 1988-2016
      • Table Effects of chemotherapy drugs on human body
  • Market trends
    • Increase in R&D activities for liver cirrhosis medication
    • Rise in awareness
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global HCC drugs market 2016
      • Table Strategic success factors of companies in global HCC drugs market
  • Key vendor analysis
    • Bayer
      • Table Bayer: Key highlights
      • Table Bayer: Strength assessment
      • Table Bayer: Strategy assessment
      • Table Bayer: Opportunity assessment
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • Johnson and Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report